Millipore Sigma Vibrant Logo

492031 NS8593 - CAS 875755-39-8 - Calbiochem

An aminobenzimidazole derivative that selectively and reversibly blocks small conductance Ca2+-activated K+ channels in a Ca2+-dependent manner.

NS8593 - CAS 875755-39-8 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

同义词: (R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine

View Products on Sigmaaldrich.com
492031
查看价格及供货情况

概述

Replacement Information

重要规格表

CAS #Empirical Formula
875755-39-8C₁₇H₁₇N₃

价格及供货情况

产品目录编号 库存情况包装 数量 / 包装 价格 数量
492031-10MGCN
正在查询供货情况......
—
目前缺货 目前缺货
有货 
停产
少量现货
供货情况有待确认
    其余：另行通知
      其余：另行通知
      另行通知
      联系客户服务
      Contact Customer Service

      		 玻璃瓶 10 mg
      正在检索价格......
      无法检索价格。
      最小订购数量为倍数
      Maximum Quantity is
      以订单确认为准 更多信息
      您节约了 ()。
       
      —
      Request Pricing
      		 —
      Description
      OverviewAn aminobenzimidazole derivative that selectively and reversibly blocks small conductance Ca2+-activated K+ channels (SK1-3; Kd = 420 nM, 600 nM, and 730 nM for SK1, SK2, SK3, respectively) in a Ca2+-dependent manner. It mediates channel gating by interacting with gating structures deep within the inner pore vestibule where Ser507 and Ala532 are deemed to be important for inhibition. Interacts at a site that is distinct from the apamin binding site in SK channels. Can access high-affinity binding sites from both the inside and outside of the cell membrane. Does not affect QT intervals, but prolongs the atrial effective refractive period and prevents acetylcholine-induced atrial fibrillations in ex vivo and in vivo models. Also shown to reversibly block TRPM7 channel (IC50 = 1.6 mM) in smooth muscle cells, primary podocytes, HEK293 cells expressing TRPM7, and ventricular myocytes in a Mg2+-dependent manner and blocks the motility of cells in culture.
      Catalogue Number492031
      Brand Family Calbiochem®
      Synonyms(R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine
      References
      ReferencesChubanov, V., et al. 2012. Brit. Journ. Pharm. 166, 1357.
      Jenkins, D., et al. 2011. Hypertension. 57, 1129.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Lasse, S., et al. 2011. J. Cardiov. Pharm. 57, 672.
      Diness, J., et al. 2010. Circ Arrhythm Electrophusiol. 3, 380.
      Ji, H., et al. 2009. Eur. J. Neurosci. 9, 1883.
      Strobaek, D., et al. 2006. Mol. Pharm. 70, 1771.
      Product Information
      CAS number875755-39-8
      FormWhite powder
      Hill FormulaC₁₇H₁₇N₃
      Chemical formulaC₁₇H₁₇N₃
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      产品目录编号 GTIN
      492031-10MGCN 04055977273564

      Documentation

      NS8593 - CAS 875755-39-8 - Calbiochem MSDS

      职位

      物料安全数据表 (MSDS) 

      NS8593 - CAS 875755-39-8 - Calbiochem 分析证书

      标题批号
      492031

      参考

      参考信息概述
      Chubanov, V., et al. 2012. Brit. Journ. Pharm. 166, 1357.
      Jenkins, D., et al. 2011. Hypertension. 57, 1129.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Lasse, S., et al. 2011. J. Cardiov. Pharm. 57, 672.
      Diness, J., et al. 2010. Circ Arrhythm Electrophusiol. 3, 380.
      Ji, H., et al. 2009. Eur. J. Neurosci. 9, 1883.
      Strobaek, D., et al. 2006. Mol. Pharm. 70, 1771.
      数据表

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision17-August-2012 JSW
      Synonyms(R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine
      DescriptionAn aminobenzimidazole derivative that selectively and reversibly blocks small conductance Ca2+-activated K+ channels (SK1-3; Kd = 420 nM, 600 nM, and 730 nM for SK1, SK2, SK3, respectively) in a Ca2+-dependent manner. It mediates channel gating by interacting with gating structures deep within the inner pore vestibule where Ser507 and Ala532 are deemed to be important for inhibition. Interacts at a site that is distinct from the apamin binding site in SK channels. Can access high-affinity binding sites from both the inside and outside of the cell membrane. Does not affect QT intervals, but prolongs the atrial effective refractive period and prevents acetylcholine-induced atrial fibrillations in ex vivo and in vivo models. Also shown to reversibly block TRPM7 channel (IC50 = 1.6 mM) in smooth muscle cells, primary podocytes, HEK293 cells expressing TRPM7, and ventricular myocytes in a Mg2+-dependent manner and blocks the motility of cells in culture.
      FormWhite powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number875755-39-8
      Chemical formulaC₁₇H₁₇N₃
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesChubanov, V., et al. 2012. Brit. Journ. Pharm. 166, 1357.
      Jenkins, D., et al. 2011. Hypertension. 57, 1129.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Jenkins, D., et al. 2011. Mol. Pharm. 79, 899.
      Lasse, S., et al. 2011. J. Cardiov. Pharm. 57, 672.
      Diness, J., et al. 2010. Circ Arrhythm Electrophusiol. 3, 380.
      Ji, H., et al. 2009. Eur. J. Neurosci. 9, 1883.
      Strobaek, D., et al. 2006. Mol. Pharm. 70, 1771.